{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=torisel&page=19", "query": { "intervention": "torisel", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 647, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=torisel&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=torisel&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T04:36:34.692Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03065387", "title": "Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "EGFR Gene Amplification", "EGFR Gene Mutation", "ERBB2 Gene Amplification", "ERBB2 Gene Mutation", "ERBB3 Gene Mutation", "ERBB4 Gene Mutation", "KRAS Gene Mutation", "Metastatic Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-10-31", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03065387" }, { "nct_id": "NCT04348292", "title": "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-01-22", "completion_date": "2022-11-04", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348292" }, { "nct_id": "NCT00382109", "title": "Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B-cell Childhood Acute Lymphoblastic Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Graft Versus Host Disease", "L1 Childhood Acute Lymphoblastic Leukemia", "L2 Childhood Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "thiotepa", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 146, "start_date": "2007-03", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Duarte, California • Oakland, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382109" }, { "nct_id": "NCT03456700", "title": "Auranofin and Sirolimus in Treating Participants With Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Serous Tumor", "Recurrent Ovarian Carcinoma" ], "interventions": [ { "name": "Auranofin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2018-03-30", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03456700" }, { "nct_id": "NCT02711826", "title": "Treg Therapy in Subclinical Inflammation in Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant", "Adult Living Donor Kidney Transplant Recipients", "Renal Transplant", "Living Kidney Donor" ], "interventions": [ { "name": "Polyclonal Regulatory T Cells", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Mycophenolic acid", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Biopsy, Kidney", "type": "PROCEDURE" }, { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "IS regimen conversion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-09-20", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711826" }, { "nct_id": "NCT00931255", "title": "Tacrolimus to Sirolimus Conversion for Delayed Graft Function", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplant", "Delayed Graft Function" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 32, "start_date": "2009-04", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931255" }, { "nct_id": "NCT00037531", "title": "Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft vs Host Disease", "Kidney Transplantation" ], "interventions": [ { "name": "Sirolimus (RAPAMUNE)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 769, "start_date": null, "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2009-08-18", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 14, "location_summary": "Los Angeles, California • San Diego, California • Stanford, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037531" }, { "nct_id": "NCT02321501", "title": "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Positive", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "ROS1 Gene Rearrangement", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-06-22", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02321501" }, { "nct_id": "NCT00612274", "title": "Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stem Cell Transplantation" ], "interventions": [ { "name": "tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 26, "start_date": "2007-10", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612274" }, { "nct_id": "NCT01767194", "title": "Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ganglioneuroblastoma", "Recurrent Neuroblastoma" ], "interventions": [ { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 73, "start_date": "2013-02-12", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2022-10-24", "last_synced_at": "2026-10-28T04:36:34.692Z", "location_count": 136, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767194" } ] }